Bone morphogenetic protein-7 inhibits telomerase activity, telomere maintenance, and cervical tumor growth

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9157-9166

  Cassar, Lucy ^a   Li, He ^a,b   Pinto, Alexander Ruvantha ^a   Nicholls, Craig ^a   Bayne, Sharyn ^a   Liu, Jun Ping ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b Department of Immunology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOGENIC PROTEIN 1; RECOMBINANT OSTEOGENIC PROTEIN 1; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER GROWTH; CELL DEATH; CONTROLLED STUDY; GENE; GENE OVEREXPRESSION; GENE SILENCING; HELA CELL; HTERT GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TELOMERE;

ANIMALS; APOPTOSIS; BONE MORPHOGENETIC PROTEIN 7; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HELA CELLS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TELOMERASE; TELOMERE; TRANSPLANTATION, HETEROLOGOUS; UTERINE CERVICAL NEOPLASMS;

EID: 56449118003     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1323     Document Type: Article

References (50)

1. Patel SR, Dressler GR. BMP7 signaling in renal development and disease. Trends Mol Med 2005;11:512-8.
2. Milan M. Sculpting a fly leg: BMP boundaries and cell death. Nat Cell Biol 2007;9:17-8.
3. Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science 2002;296:1646-7.
4. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;19:2783-810.
5. Foletta VC, Lim MA, Soosairajah J, et al. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 2003;162:1089-98.
6. Wen Z, Han L, Bamburg JR, Shim S, Ming GL, Zheng JQ. BMP gradients steer nerve growth cones by a balancing act of LIM kinase and Slingshot phosphatase on ADF/cofilin. J Cell Biol 2007;178:107-19.
7. Lu M, Lin SC, Huang Y, et al. XIAP induces NF-κB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007;26:689-702.
8. Qiu T, Grizzle WE, Oelschlager DK, Shen X, Cao X. Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1. EMBO J 2007;26:346-57.
9. Alarmo EL, Rauta J, Kauraniemi P, Karhu R, Kuukasjarvi T, Kallioniemi A. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006;45:411-9.
10. Rothhammer T, Wild PJ, Meyer S, et al. Bone morphogenetic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark 2007;3:111-7.
11. Grijelmo C, Rodrigue C, Svrcek M, et al. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal 2007;19:1722-32.
12. Ro TB, Holt RU, Brenne AT, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004;23:3024-32.
13. Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 2004;23:9326-35.
14. Beck SE, Jung BH, Del Rosario E, Gomez J, Carethers JM. BMP-induced growth suppression in colon cancer cells is mediated by p21(WAF1) stabilization and modulated by RAS/ERK. Cell Signal 2007;19:1465-72.
15. Jena N, Martin-Seisdedos C, McCue P, Croce CM. BMP7 null mutation in mice: developmental defects in skeleton, kidney, and eye. Exp Cell Res 1997;230:28-37.
16. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007;171:1047-57.
17. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-61.
18. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P. Diverse Biological Effect and Smad Signaling of Bone Morphogenetic Protein 7 in Prostate Tumor Cells. Cancer Res 2005;65:5769-77.
19. Buijs JT, Henriquez NV, van Overveld PG, et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007;67:8742-51.
20. Blackburn EH. Switching and signaling at the telomere. Cell 2001;106:661-73.
21. Xu L, Blackburn EH. Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres. Mol Cell 2007;28:315-27.
22. Negrini S, Ribaud V, Bianchi A, Shore D. DNA breaks are masked by multiple Rap1 binding in yeast: implications for telomere capping and telomerase regulation. Genes Dev 2007;21:292-302.
23. Morrish TA, Garcia-Perez JL, Stamato TD, Taccioli GE, Sekiguchi J, Moran JV. Endonuclease-independent LINE-1 retrotransposition at mammalian telomeres. Nature 2007;446:208-12.
24. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006;5:577-84.
25. Hahn WC. Telomere and telomerase dynamics in human cells. Curr Mol Med 2005;5:227-31.
26. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 1996;16:2932-9.
27. Li H, Pinto AR, Duan W, Li J, Toh BH, Liu JP. Telomerase down-regulation does not mediate PC12 pheochromocytoma cell differentiation induced by NGF, but requires MAP kinase signalling. J Neurochem 2005;95:891-901.
28. Kyo S, Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: How can we apply them for cancer therapy? Oncogene 2002;21:688-97.
29. Takakura M, Kyo S, Inoue M, Wright WE, Shay JW. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 2005;25:8037-43.
30. Li H, Xu D, Li J, Berndt MC, Liu JP. Transforming growth factor β suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J Biol Chem 2006;281:25588-600.
31. Li H, Liu JP. Mechanisms of action of TGF-β in cancer: evidence for Smad3 as a repressor of the hTERT gene. Ann N Y Acad Sci 2007;1114:56-68.
32. Li H, Xu D, Toh BH, Liu JP. TGF-β and cancer: is Smad3 a repressor of hTERT gene? Cell Res 2006;16:169-73.
33. Hu B, Tack DC, Liu T, Wu Z, Ullenbruch MR, Phan SH. Role of Smad3 in the regulation of rat telomerase reverse transcriptase by TGFβ. Oncogene 2006;25:1030-41.
34. Fujiki T, Miura T, Maura M, et al. TAK1 represses transcription of the human telomerase reverse transcriptase gene. Oncogene 2007;26:5258-66.
35. Lacerte A, Korah J, Roy M, Yang XJ, Lemay S, Lebrun JJ. Transforming growth factor-β inhibits telomerase through SMAD3 and E2F transcription factors. Cell Signal 2008;20:50-9.
36. Li H, Zhao LL, Funder JW, Liu JP. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem 1997;272:16729-32.
37. Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol 1998;16:743-7.
38. Ma T, Gutnick J, Salazar B, et al. Modulation of allograft incorporation by continuous infusion of growth factors over a prolonged duration in vivo. Bone 2007;41:386-92.
39. Simic P, Culej JB, Orlic I, et al. Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. J Biol Chem 2006;281:25509-21.
40. Li S, Crothers J, Haqq CM, Blackburn EH. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 2005;280:23709-17.
41. Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent telomerase activity. Oncogene 2002;21:3130-8.
42. Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005;42:1127-36.
43. Pallini R, Sorrentino A, Pierconti F, et al. Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. Int J Cancer 2006;118:2158-67.
44. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60.
45. Krimpenfort P, Ijpenberg A, Song JY, et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007;448:943-6.
46. Smogorzewska A, de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J 2002;21:4338-48.
47. Jacobs JJ, de Lange T. p16INK4a as a second effector of the telomere damage pathway. Cell Cycle 2005;4:1364-8.
48. de Lange T. Protection of mammalian telomeres. Oncogene 2002;21:532-40.
49. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-5.
50. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007;448:1068-71.